Clever Culture Systems Ltd
16 Anster St
Adelaide SA 5000
www.cleverculturesystems.com

CLEVER CULTURE SYSTEMS

ASX:CC5

MANAGING DIRECTOR'S PRESENTATION – 2026 AGM

Adelaide, Australia, 17 November 2026: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) is pleased to provide the attached Managing Director's presentation, being provided at today's 2026 Annual General Meeting.

Approved for release by the CCS Board.

– ENDS –

About Clever Culture Systems
Clever Culture Systems (CCS) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading. The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

Clever Culture Systems
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@cleverculturesystems.com

CEO Presentation

AI-powered microbiology

Revolutionising microbial quality control in pharmaceutical manufacturing

Annual General Meeting

17 November 2026



Commercial traction

H1 FY27 progressing as a step-change in sales performance

H1 FY27 SALES AND NEW EVALUATIONS

8 **APAS® instruments**
matching full-year FY26

✓ ✓ ✓ ✓ ✓ ✓ ☐ ☐

✓ **6 completed** ☐ **2 more expected in 2026**

COMPLETED

- 3 — Sales completed and invoiced in Q1 FY27 to Novo and AstraZeneca
- 2 — Purchase orders received from existing global pharma customers during Q2 FY27
- 1 — Instrument committed by PSC Biotech under Sales Agent Agreement, delivery expected H2 FY27

EXPECTED BY END OF DECEMBER 2026

- 1 — Additional purchase order, new customer
- 1 — New Top-20 global pharma customer order to commence paid evaluation

APAS® Revolution

Substantial growth opportunity unlocked

Built on proven APAS® technology, funded and launching H1 CY2028



$4.3B
revised increased TAM

~50%
uplift to APAS® TAM

3,400
instrument opportunity

<2 yrs
payback after launch

TIMELINE

Nov 2026

$2.6m funding package secured

Next

- External engineering partner selected
- Commence R&D

CY2027

- Pre-production units with customers
- Pre-launch at conferences

CY2028

- Product launch
- Customer advocacy
- Product sales start

Within 2 years

Development cost paid back after launch

Expanded opportunity

Targeting a 5,700 APAS® instrument TAM: $4.3B

APAS® platforms to address the entire market opportunity

APAS® Revolution
3,400 instrument opportunity / $1.5B

APAS® Independence
2,300 instrument opportunity / $2.8B



Segmentation based on number of environmental monitoring culture plates assessed daily

Same revenue model

One revenue model across both APAS instruments

Independence and Revolution share a broadly equivalent revenue split[1]



APAS® Revolution

APAS® Independence

Product / Service	Description	Revenue Model	Approx. Split
APAS® Instruments	APAS® Independence and APAS® Revolution	Upfront Capex *(inc. financing options)*	40%
APAS Apps®	AI Software Licence	ARR	40%
APAS Service	Support and maintenance services	ARR	15%
Implementation Services	Instrument connectivity, technical data and validation support	One-off	5%

[1] *Approximate revenue split over 7 years (expected life of instrument); specific splits may change once APAS® Revolution is commercially launched*

TODAY

Today: APAS® proven and building trust with global pharma



37 instruments installed

9 top-20 pharma customers

GMP use routinely by customers

NEXT

Scale: building on that success to increase global market opportunity



Second product, $4.3bn TAM

Recurring revenue scaling

Broad based customer growth